240 related articles for article (PubMed ID: 35967571)
21. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of
Murbach B; Duarte G; Palma LC; Miranda E; Duffles G; Furlin GP; Toni I; De Souza C; Binelli L; Bassan VL; de Castro FA; de Figueiredo-Pontes LL; Pagnano KBB
Front Oncol; 2024; 14():1393191. PubMed ID: 38779092
[TBL] [Abstract][Full Text] [Related]
23. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Soverini S; De Santis S; Martelli M; Monaldi C; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Bruno S; Venturi C; Machova Polakova K; Ernst T; Maar D; Corner A; Cavo M
Leukemia; 2022 Sep; 36(9):2250-2260. PubMed ID: 35908105
[TBL] [Abstract][Full Text] [Related]
24. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
25. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
27. Digital PCR for
Kockerols CCB; Valk PJM; Levin MD; Pallisgaard N; Cornelissen JJ; Westerweel PE
Hemasphere; 2020 Dec; 4(6):e496. PubMed ID: 33283168
[TBL] [Abstract][Full Text] [Related]
28. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
29. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
30. Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
Abruzzese E; Bocchia M; Trawinska MM; Raspadori D; Bondanini F; Sicuranza A; Pacelli P; Re F; Cavalleri A; Farina M; Malagola M; Russo D; De Fabritiis P; Bernardi S
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627140
[TBL] [Abstract][Full Text] [Related]
31. Molecular monitoring in CML and the prospects for treatment-free remissions.
Deininger MW
Hematology Am Soc Hematol Educ Program; 2015; 2015():257-63. PubMed ID: 26637731
[TBL] [Abstract][Full Text] [Related]
32. De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.
Luo J; Du X; Lou J; Wu J; Ma L; Huang J; Wang L; Tu C; Liu Z; Chen L; Tan Y; Luo D; Liang H; Yin C; Cao R; Zhou X; Liu Q; Liu X; Xu N
EJHaem; 2022 Nov; 3(4):1220-1230. PubMed ID: 36467815
[No Abstract] [Full Text] [Related]
33. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.
Shelton DN; Bhagavatula P; Sepulveda N; Beppu L; Gandhi S; Qin D; Hauenstein S; Radich J
PLoS One; 2022; 17(3):e0265278. PubMed ID: 35298544
[TBL] [Abstract][Full Text] [Related]
34. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
35. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
36. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
37. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
38. Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical
Petiti J; Lo Iacono M; Dragani M; Pironi L; Fantino C; Rapanotti MC; Quarantelli F; Izzo B; Divona M; Rege-Cambrin G; Saglio G; Gottardi EM; Cilloni D; Fava C
J Clin Med; 2020 May; 9(5):. PubMed ID: 32414125
[No Abstract] [Full Text] [Related]
39. Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.
Jun K; Ya-Zhen Q; Xiao-Su Z; Hong-Xia S; Yue-Yun L; Kai-Yan L; Xiao-Jun H; Hao J
Ther Adv Hematol; 2021; 12():2040620720986643. PubMed ID: 33613929
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.
Millot F; Suttorp M; Ragot S; Leverger G; Dalle JH; Thomas C; Cheikh N; Nelken B; Poirée M; Plat G; Versluys B; Lausen B; Borisevich M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
